Prostate cancer spit test starts early trial
Aspit test to detect men at increased risk of prostate cancer has started early trials. The new DNA test looks for high-risk genes that are thought to affect one in every 100 men, BBC reported.
Three hundred men are taking part in the trials, from three London GP surgeries.
Developing better diagnostic tests that could be used as part of a nationwide screening programmer is a research priority for prostate cancer.
At present, there is no single, reliable test for prostate cancer. The PSA blood test, biopsies and physical examinations are all used.
But the PSA can give false positives and sometimes misses more aggressive cases.
The new DNA test was created by a group of international scientists based at the Institute of Cancer Research (ICR) in London.
They studied more than 140,000 men and identified 63 new genetic variations that can increase the risk of prostate cancer.
The DNA test combines those variants with more than 100 others previously linked to prostate cancer.
Ros Elees, professor of oncogenetics at the ICR, said the study was ‘very significant’. could ultimately be employed in the design of new treatments”.
The study — published in the journal Nature Genetics — was funded by the National Cancer Institute in the US, with additional support from the European Research Council, Cancer Research UK and Prostate Cancer UK.
Dr. Iain Frame, director of research at Prostate Cancer UK said, “This new research could help men to understand their individual genetic risk of prostate cancer, which could prompt them to speak to their GP about the disease.
“Given that one in eight men will be diagnosed with prostate cancer in their lifetime, we urgently need more accurate diagnostic tests which are suitable for use in a nationwide screening programmer.”
Carl Alexander from Cancer Research UK, said the study was ‘an exciting example’ of how research can find clues in our genes to help us uncover those more likely to develop the disease.
“The next steps should be to understand how this research can be developed into tests which could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.”